ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
176 hedge funds and large institutions have $1.4B invested in ChemoCentryx, Inc. in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 71 increasing their positions, 62 reducing their positions, and 34 closing their positions.
63% more call options, than puts
Call options by funds: $44.2M | Put options by funds: $27.1M
15% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 62
7% less funds holding
Funds holding: 190 → 176 (-14)
27% less capital invested
Capital invested by funds: $1.92B → $1.4B (-$524M)
38% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 34
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$32.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27.4M |
| 3 |
HM
HealthCor Management
New York
|
+$20.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$16M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$34.1M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$20.3M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$20.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$18.2M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.76M |
CCXI Hedge Fund Activity: Q1 2022 in Review
176 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q1 2022, worth a combined $1.4B — down 27% from $1.92B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of CCXI and 21 opened new positions — a net loss of 13 holders — while 62 trimmed existing stakes and 71 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $32.5M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $34.1M sold.
- 176 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q1 2022, down from 190 in Q4 2021.
- Funds reported $1.4B of ChemoCentryx, Inc. stock for Q1 2022, down 27% quarter-over-quarter.
- 21 funds opened new ChemoCentryx, Inc. positions in Q1 2022 and 34 closed out, a net change of -13 holders.
- The largest ChemoCentryx, Inc. buyer in Q1 2022 was RA Capital Management, an estimated $32.5M added.
- The largest ChemoCentryx, Inc. seller in Q1 2022 was Farallon Capital Management, an estimated $34.1M sold.
Based on aggregated 13F filings for Q1 2022.